Abbonarsi

Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction - 05/08/19

Doi : 10.1016/j.ahj.2019.06.004 
Trygve S. Hall, MD, PhD a, , Thomas G. von Lueder, MD, PhD a, Faiez Zannad, MD, PhD b, c, d, e, Patrick Rossignol, MD, PhD b, c, d, e, Kevin Duarte, MSc b, c, d, e, Tahar Chouihed, MD b, e, f, Scott D. Solomon, MD g, Kenneth Dickstein, MD, PhD h, i, Dan Atar, MD, PhD a, j, Stefan Agewall, MD, PhD a, j, Nicolas Girerd, MD, PhD b, c, d, e

for the High-Risk Myocardial Infarction Database Initiative investigators

a Department of Cardiology B, Oslo University Hospital, Oslo, Norway 
b INSERM, Centre d'Investigation Clinique -1433 and Unité 1116, Nancy, France 
c CHU Nancy, Institut Lorrain du Cœur et des Vaisseaux, Vandoeuvre lès Nancy, France 
d Université de Lorraine, Nancy, France 
e F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) Network, Nancy, France 
f Emergency Department, CHU Nancy, Nancy, France 
g Division of Cardiovascular Medicine, Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA 
h Division of Cardiology, Stavanger University Hospital, Stavanger, Norway 
i Institute of Internal Medicine, University of Bergen, Bergen, Norway 
j Institute of Clinical Medicine, University of Oslo, Oslo, Norway 

Reprint requests: Dr Trygve Sundby Hall, Division of Medicine, Oslo University Hospital, PO Box 4956 Nydalen, N-0424 Oslo, Norway.Division of Medicine, Oslo University HospitalNydalenN-0424 OsloNorway

Abstract

Background

Reduced left ventricular ejection fraction (LVEF) after acute myocardial infarction (MI) increases risk of cardiovascular (CV) hospitalizations, but evidence regarding its association with non-CV outcome is scarce. We investigated the association between LVEF and adjudicated cause-specific hospitalizations following MI complicated with low LVEF or overt heart failure (HF).

Methods

In an individual patient data meta-analysis of 19,740 patients from 3 large randomized trials, Fine and Gray competing risk modeling was performed to study the association between LVEF and hospitalization types.

Results

The most common cause of hospitalization was non-CV (n = 2,368 for HF, n = 1,554 for MI, and n = 3,703 for non-CV). All types of hospitalizations significantly increased with decreasing LVEF. The absolute risk increase associated with LVEF ≪25% (vs LVEF ≫35%) was 15.5% (95% CI 13.4-17.5) for HF, 4.7% (95% CI 3.0-6.4) for MI, and 10.4% (95% CI 8.0-12.8) for non-CV hospitalization. On a relative scale, after adjusting for confounders, each 5-point decrease in LVEF was associated with an increased risk of HF (hazard ratio [HR] 1.15, 95% CI 1.12-1.18), MI (HR 1.06, 95% CI 1.03-1.10), and non-CV hospitalization (HR 1.03, 95% CI 1.01-1.05).

Conclusions

In a high-risk population with complicated acute MI, the absolute risk increase in non-CV hospitalizations associated with LVEF ≪25% was two thirds of the absolute risk increase in HF hospitalizations and twice the absolute risk increase in MI hospitalizations. LVEF was an independent predictor of all types of hospitalization and appears as an integrative marker of sicker patient status.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2019  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 215

P. 83-90 - Settembre 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165/bFGF cDNA for the treatment of refractory coronary artery disease
  • Krzysztof Kuku?a, Arkadiusz Urbanowicz, Mariusz K?opotowski, Maciej D?browski, Jerzy Pr?gowski, Jacek K?dziela, Zbigniew Chmielak, Adam Witkowski, Witold Ru?y??o
| Articolo seguente Articolo seguente
  • Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial
  • Abhinav Sharma, Emil Hagström, Daniel M. Wojdyla, Megan L. Neely, Robert A. Harrington, Lars Wallentin, John H. Alexander, Shaun G. Goodman, Renato D. Lopes, Apixaban for Prevention of Acute Ischemic Safety Events APPRAISE-2 Steering Committee and Investigators

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.